scholarly journals HIV PrEP is more than ART‐lite: Longitudinal study of real‐world PrEP services data identifies missing measures meaningful to HIV prevention programming

2021 ◽  
Vol 24 (10) ◽  
Author(s):  
Jason Bailey Reed ◽  
Prakriti Shrestha ◽  
Daniel Were ◽  
Tafadzwa Chakare ◽  
Jane Mutegi ◽  
...  
AIDS Care ◽  
2012 ◽  
Vol 25 (2) ◽  
pp. 207-214 ◽  
Author(s):  
Jessica A. Fehringer ◽  
Stella Babalola ◽  
Caitlin E. Kennedy ◽  
Lusajo J. Kajula ◽  
Jessie K. Mbwambo ◽  
...  

Author(s):  
Jon Froehlich ◽  
Eric Larson ◽  
Elliot Saba ◽  
Tim Campbell ◽  
Les Atlas ◽  
...  

Author(s):  
Gonzalo J. Martinez ◽  
Stephen M. Mattingly ◽  
Shayan Mirjafari ◽  
Subigya K. Nepal ◽  
Andrew T. Campbell ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e89180 ◽  
Author(s):  
Willis Omondi Odek ◽  
George N. Githuka ◽  
Lisa Avery ◽  
Peter K. Njoroge ◽  
Lombe Kasonde ◽  
...  

2021 ◽  
Author(s):  
Sabrina E Racine-Brzostek ◽  
Jim Yee ◽  
Ashley Sukhu ◽  
Yuqing Qiu ◽  
Sophie Rand ◽  
...  

Longitudinal studies are needed to evaluate the SARS-CoV-2 mRNA vaccine antibody response under real-world conditions. This longitudinal study investigated the quantity and quality of SARS-CoV-2 antibody response in 846 specimens from 350 subjects: comparing BNT162b2-vaccinated individuals (19 previously diagnosed with COVID-19 [RecoVax]; 49 never been diagnosed [NaiveVax]) to 122 hospitalized unvaccinated (HospNoVax) and 160 outpatient unvaccinated (OutPtNoVax) COVID-19 patients. NaiveVax experienced a delay in generating SARS-CoV-2 total antibody levels (TAb) and neutralizing antibodies (SNAb) after the 1st vaccine dose (D1), but a rapid increase in antibody levels was observed after the 2nd dose (D2). However, these never reached the robust levels observed in RecoVax. In fact, NaiveVax TAb and SNAb levels decreased 4-weeks post-D2 (p=0.003;p<0.001). For the most part, RecoVax TAb persisted throughout this study, after reaching maximal levels 2-weeks post-D2; but SNAb decreased significantly ~6-months post-D1 (p=0.002). Although NaiveVax avidity lagged behind that of RecoVax for most of the follow-up periods, NaiveVax did reach similar avidity by ~6-months post-D1. These data suggest that one vaccine dose elicits maximal antibody response in RecoVax and may be sufficient. Also, despite decreasing levels in TAb and SNAb overtime, long-term avidity maybe a measure worth evaluating and possibly correlating to vaccine efficacy.


2020 ◽  
Author(s):  
Jef Vanhamel ◽  
Anke Rotsaert ◽  
Thijs Reyniers ◽  
Christiana Nöstlinger ◽  
Marie Laga ◽  
...  

Abstract Background: Strengthening HIV prevention is imperative given the continued high HIV incidence worldwide. The introduction of oral PrEP as a new biomedical HIV prevention tool can be a potential game changer because of its high clinical efficacy and the feasibility of its provision to different key populations. Documenting the existing experience with PrEP service delivery in a variety of real-world settings will inform how its uptake and usage can be maximised. Methods: We conducted a scoping review using the five-step framework provided by Arksey and O’Malley. We systematically searched the existing peer-reviewed international and grey literature describing the implementation of real-world PrEP service delivery models reporting on four key components: the target population of PrEP services, the setting where PrEP was delivered, PrEP providers’ professionalisation and PrEP delivery channels. We restricted our search to English language articles. No geographical or time restrictions were set.Results: This review included 33 articles for charting and analysing of the results. The identified service delivery models showed that PrEP services mainly targeted people at high risk of HIV acquisition, with some models targeting specific key populations, mainly men who have sex with men. PrEP was often delivered centralised and in a clinical or hospital setting. Yet also community-based as well as home-based PrEP delivery models were reported. Providers of PrEP were mainly clinically trained health professionals, but in some rare cases community workers and lay providers also delivered PrEP. In general, in-person visits were used to deliver PrEP. More innovative digital options using mHealth and telemedicine approaches to deliver specific parts of PrEP services are currently being applied in a minority of the service delivery models in mainly high-resource settings.Conclusions: A range of possible combinations was found between all four components of PrEP service delivery models. This reflects differentiation of care according to different contextual settings. More research is needed on how integration of services in these contexts could be expanded and optimised to respond to key populations with unmet HIV prevention needs in different settings.


Author(s):  
Carina Price ◽  
Eleonora Montagnani ◽  
Ana Martinez Santos ◽  
Prof Chris Nester ◽  
Stewart Morrison

2017 ◽  
Vol 31 (6) ◽  
pp. 275-281 ◽  
Author(s):  
Thomas E. Freese ◽  
Howard Padwa ◽  
Brandy T. Oeser ◽  
Beth A. Rutkowski ◽  
Marya T. Schulte

Sign in / Sign up

Export Citation Format

Share Document